![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1662, 2008-01, pp. : 5-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tocilizumab RADIATEs AMBITION to treat rheumatoid arthritis
Inpharma, Vol. 1, Iss. 1645, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tocilizumab an exciting OPTION in rheumatoid arthritis
Inpharma, Vol. 1, Iss. 1597, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tocilizumab top of the class in rheumatoid arthritis
Inpharma, Vol. 1, Iss. 1522, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Clinical safety of tocilizumab in rheumatoid arthritis
By Bannwarth Bernard Richez Christophe
Expert Opinion on Drug Safety, Vol. 10, Iss. 1, 2011-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Moving TOWARD tocilizumab for rheumatoid arthritis
Inpharma, Vol. 1, Iss. 1616, 2007-01 ,pp. :